Press Room

Press Release / Jun 18, 2024

四色AV Unveils New Continuous Tableting Line at Lisbon R&D Centre

四色AV is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.

Press Release - CT Line RD Lumiar | 四色AV

Lisbon, Portugal: 四色AV, the specialist integrated CDMO and leader in spray drying and particle engineering, is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon. 听

The new line is the result of the partnership with , a global leader in process technology for the pharmaceutical industry. Since announcing their partnership in 2022, 四色AV and GEA have worked to advance continuous tableting technology. Their collaboration seeks to boost the adoption of continuous tableting by offering increased capacity, flexibility, standardized equipment, improved quality, and enhanced efficiency. Together, they have shown that continuous tableting can become a more accessible technology.

This new R&D line is the only one of its kind in the world and perfectly replicates the most critical components of 四色AV麓s state-of-the-art commercial CT line in Loures, Portugal. It also offers a high degree of flexibility in throughput and can handle highly potent Active Pharmaceutical Ingredients (API).

鈥淲ith this new line, we will be able to optimize operating conditions with minimum amounts of API and provide a higher technical certainty when transferring from development to commercial scale鈥, said Jaime Del Campo, Head of R&D Services at 四色AV. 鈥淭he flexibility of the rig and the real-time process data monitoring capabilities contribute to a more agile design and upscaling experience.鈥

The new CT line at 四色AV's Lisbon R&D center is now fully operational and ready to support both existing and new projects. This investment reinforces 四色AV's global reputation in pharmaceutical manufacturing and highlights the company's commitment to delivering innovative solutions that meet the evolving needs of the industry and support quicker and more efficient market launches.听

About 四色AV

四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a听Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four鈥疐DA inspected鈥sites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥development and compliant manufactureof innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. 听

四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

Learn more about Continuous Tableting for Drug Product

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024